RT Journal Article
T1 COVID-19 in Adults With Congenital Heart Disease.
A1 Broberg, Craig S
A1 Kovacs, Adrienne H
A1 Sadeghi, Soraya
A1 Rosenbaum, Marlon S
A1 Lewis, Matthew J
A1 Carazo, Matthew R
A1 Rodriguez, Fred H
A1 Halpern, Dan G
A1 Feinberg, Jodi
A1 Galilea, Francisca Arancibia
A1 Baraona, Fernando
A1 Cedars, Ari M
A1 Ko, Jong M
A1 Porayette, Prashob
A1 Maldonado, Jennifer
A1 Sarubbi, Berardo
A1 Fusco, Flavia
A1 Frogoudaki, Alexandra A
A1 Nir, Amiram
A1 Chaudhry, Anisa
A1 John, Anitha S
A1 Karbassi, Arsha
A1 Hoskoppal, Arvind K
A1 Frischhertz, Benjamin P
A1 Hendrickson, Benjamin
A1 Bouma, Berto J
A1 Rodriguez-Monserrate, Carla P
A1 Broda, Christopher R
A1 Tobler, Daniel
A1 Gregg, David
A1 Martinez-Quintana, Efren
A1 Yeung, Elizabeth
A1 Krieger, Eric V
A1 Ruperti-Repilado, Francisco J
A1 Giannakoulas, George
A1 Lui, George K
A1 Ephrem, Georges
A1 Singh, Harsimran S
A1 Almeneisi, Hassan Mk
A1 Bartlett, Heather L
A1 Lindsay, Ian
A1 Grewal, Jasmine
A1 Nicolarsen, Jeremy
A1 Araujo, John J
A1 Cramer, Jonathan W
A1 Bouchardy, Judith
A1 Al Najashi, Khalid
A1 Ryan, Kristi
A1 Alshawabkeh, Laith
A1 Andrade, Lauren
A1 Ladouceur, Magalie
A1 Schwerzmann, Markus
A1 Greutmann, Matthias
A1 Meras, Pablo
A1 Ferrero, Paolo
A1 Dehghani, Payam
A1 Tung, Poyee P
A1 Garcia-Orta, Rocio
A1 Tompkins, Rose O
A1 Gendi, Salwa M
A1 Cohen, Scott
A1 Klewer, Scott
A1 Hascoet, Sebastien
A1 Mohammadzadeh, Shabnam
A1 Upadhyay, Shailendra
A1 Fisher, Stacy D
A1 Cook, Stephen
A1 Cotts, Timothy B
A1 Aboulhosn, Jamil A
K1 COVID-19
K1 adult congenital heart disease
K1 coronavirus
K1 hospitalization
AB Adults with congenital heart disease (CHD) have been considered potentially high risk for novel coronavirus disease-19 (COVID-19) mortality or other complications. This study sought to define the impact of COVID-19 in adults with CHD and to identify risk factors associated with adverse outcomes. Adults (age 18 years or older) with CHD and with confirmed or clinically suspected COVID-19 were included from CHD centers worldwide. Data collection included anatomic diagnosis and subsequent interventions, comorbidities, medications, echocardiographic findings, presenting symptoms, course of illness, and outcomes. Predictors of death or severe infection were determined. From 58 adult CHD centers, the study included 1,044 infected patients (age: 35.1 ± 13.0 years; range 18 to 86 years; 51% women), 87% of whom had laboratory-confirmed coronavirus infection. The cohort included 118 (11%) patients with single ventricle and/or Fontan physiology, 87 (8%) patients with cyanosis, and 73 (7%) patients with pulmonary hypertension. There were 24 COVID-related deaths (case/fatality: 2.3%; 95% confidence interval: 1.4% to 3.2%). Factors associated with death included male sex, diabetes, cyanosis, pulmonary hypertension, renal insufficiency, and previous hospital admission for heart failure. Worse physiological stage was associated with mortality (p = 0.001), whereas anatomic complexity or defect group were not. COVID-19 mortality in adults with CHD is commensurate with the general population. The most vulnerable patients are those with worse physiological stage, such as cyanosis and pulmonary hypertension, whereas anatomic complexity does not appear to predict infection severity.
YR 2021
FD 2021
LK http://hdl.handle.net/10668/17438
UL http://hdl.handle.net/10668/17438
LA en
DS RISalud
RD Apr 19, 2025